GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Last trade$49.33
Day change-$1.085 (-2.15%)
Day range$49.27 – $50.50
Volume1,886,346
Market cap$101.05B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GSK.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GSK.
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
GSK reported Q3 2026 earnings with 5% sales growth to GBP 8.9 billion, reconfirming full-year guidance. The company is accelerating its R&D pipeline with 18 phase 3 clinical trials started in 2026 and expects 22 by year-end. Specialty medicines, particularly long-acting HIV treatments like Cabenuva, drove 15% growth and higher margins. Management's Accelerate Growth restructuring program redirects cost savings toward late-stage drug development while maintaining operating profit margins, positioning the company for sustained long-term value creation.
Ziphius, a biotechnology company specializing in self-amplifying RNA (saRNA), announced the appointment of Antoon Loomans to its Board of Directors. Loomans, a veteran vaccine industry executive with 30 years of experience including 27 years at GSK and recent role at VaxCo (acquired by Eli Lilly for $1.55B), will lead commercial development in the US focusing on strategic partnerships and licensing. The appointment comes as Ziphius advances its lead Chlamydia trachomatis vaccine candidate toward clinical trials and conducts a €30 million fundraising round.
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.4518
Jan 7, 2027
recurring
Aug 14, 2026
$0.4501
Oct 8, 2026
recurring
May 15, 2026
$0.455
Jul 9, 2026
recurring
Feb 20, 2026
$0.4776
Apr 9, 2026
recurring
Nov 14, 2025
$0.4331
Jan 8, 2026
recurring
Stock splits
Historical share-structure events and their execution dates.